Sensei Biotherapeutics is a clinical-stage immunotherapy biotechnology company that is developing a pipeline of investigational medicines that work by “awakening” the immune system to defend and defeat cancer and infectious diseases. The company has developed a unique drug discovery approach, ImmunoPhage™️, that generates powerful and specific immune responses.
ImmunoPhage™ product pipeline:
- SNS-301 (ASPH; HPV- specific E6/E7)
- 1st Line Head & Neck Cancer in combination with pembrolizumab.
- Head & Neck Cancer Neoadjuvant evaluating combination strategies.
- SNS-401 (Cocktail with MCPyV)
- Merkel Cell Carcinoma.
- Nanobodies & Antibodies